Tempus AI, Inc. (TEM)
Automate Your Wheel Strategy on TEM
With Tiblio's Option Bot, you can configure your own wheel strategy including TEM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEM
- Rev/Share 5.4907
- Book/Share 1.7854
- PB 34.0644
- Debt/Equity 0.1785
- CurrentRatio 1.5406
- ROIC -0.1557
- MktCap 10222166409.0
- FreeCF/Share -0.4017
- PFCF -146.7858
- PE -52.7954
- Debt/Assets 0.034
- DivYield 0
- ROE -1.0712
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TEM | BTIG Research | -- | Buy | -- | $60 | April 21, 2025 |
| Downgrade | TEM | JP Morgan | Overweight | Neutral | $50 | $55 | Feb. 25, 2025 |
| Downgrade | TEM | William Blair | Outperform | Market Perform | -- | -- | Feb. 12, 2025 |
| Resumed | TEM | TD Cowen | -- | Buy | $58 | $74 | Feb. 5, 2025 |
| Initiation | TEM | Wolfe Research | -- | Outperform | -- | $60 | Dec. 13, 2024 |
| Initiation | TEM | Guggenheim | -- | Buy | -- | $74 | Dec. 9, 2024 |
| Downgrade | TEM | BofA Securities | Buy | Neutral | $45 | $60 | Oct. 2, 2024 |
News
TEMPUS FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Tempus Investors of the August 11th Deadline and Urges Investors to Contact the Firm
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options
Read More
Tempus AI: Buy or Sell TEM Stock At $65?
Published: August 11, 2025 by: Forbes
Sentiment: Positive
Tempus AI stock has increased by 10% over the past week, fueled by impressive quarterly results and a raised sales forecast for the entire year. The company is now predicting an 82% year-over-year increase in sales, amounting to approximately $126 million.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company")(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
INVESTOR DEADLINE TOMORROW: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Aug. 11, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the "Class Period"), have until this upcoming Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v.
Read More
TEM Securities Lawsuit Filed Against Tempus AI, Inc. Contact the DJS Law Group to Discuss Your Rights
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 11, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of securities laws. Shareholders who purchased the Company's securities between August 6, 2024, and May 27, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 12, 2025.
Read More
TEM Investors Have Opportunity to Lead Tempus AI, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 11, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 12, 2025.
Read More
Deadline Soon: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Published: August 08, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 12, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON TEMPUS AI, INC. (TEM), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRA.
Read More
Tempus AI, Inc. (TEM) Q2 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Tempus AI, Inc. (NASDAQ:TEM ) Q2 2025 Earnings Conference Call August 8, 2025 8:00 PM ET Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eric P. Lefkofsky - Co-Founder, CEO, President & Chairman James Rogers - Chief Financial Officer Conference Call Participants Andrew Frederick Brackmann - William Blair & Company L.L.C.
Read More
Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key Metrics
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.
Read More
TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery
Published: August 08, 2025 by: Schwab Network
Sentiment: Positive
George Congdon joins Morning Movers to look at an AI player in the healthcare space: Tempus AI (TEM). Shares of TEM have rallied higher after its 2Q earnings.
Read More
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Aug. 6, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, all dates inclusive (the "Class Period"), have until Tuesday, August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v.
Read More
Tempus AI, Inc. (TEM) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 6, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM). IF YOU SUFFERED A LOSS ON YOUR TEMPUS INVESTMENTS, CLICK HERE BEFORE AUGUST 12, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company")(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Tempus AI Targets Breast Cancer With Expanded Next - AI Platform
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM expands its AI-driven Tempus Next platform into breast cancer, targeting key testing gaps to improve care delivery.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”)(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Deadline Alert: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”).
Read More
Tempus AI: Next Leg Up
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Positive
Tempus AI is appealing after a 10% pullback, seeing it as an opportunity following strong Q1 results and a short report-driven dip. The precision medicine company should top Q2 estimates, especially with full Ambry Genetics revenue and the expanded $200M AstraZeneca data licensing deal fueling growth. The stock valuation is attractive at 6.5x 2026 sales estimates, making Tempus AI a compelling play as it builds its AI-driven medical platform.
Read More
Tempus AI, Inc. (TEM) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 31, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM) have opportunity to lead the securities fraud class action lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. ("Tempus" or the "Company")(NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
TEM Investors Have Opportunity to Lead Tempus AI, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 31, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2024 and May 27, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 12, 2025.
Read More
Tempus AI, Inc. (TEM) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , July 30, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
Tempus AI: Data‑Driven Margin Lift, But Cash Burn Extends My Hold Stance
Published: July 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Tempus AI continues strong revenue growth, driven by its high-margin Data and Services segment and recent Ambry acquisition, but profitability remains elusive. Operational progress is evident, with expanding pharma partnerships and a growing AI-driven data platform, yet financial risks persist due to high cash burn and new debt. Upcoming Q2 results will be critical to assess sustainable profitability, margin stability, and growth in high-value contracts and test reimbursement rates.
Read More
TEMPUS AI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM
Published: July 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, July 29, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company's shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
Read More
Tempus AI Taps Growing ICI Market With New xM Assay
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
TEM launches xM, a liquid biopsy assay to monitor real-time response to ICI therapy in advanced solid tumors.
Read More
Tempus AI: Sustaining Growth Momentum With Acquisitions & Partnerships
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Positive
I am strongly bullish on Tempus AI due to its strategic partnerships, Ambry Genetics acquisition, and leadership in AI-driven precision oncology. Tempus' collaborations and acquisitions position it at the forefront of a rapidly growing oncology market, with an expected 80% revenue growth in 2025. Despite current net losses from high R&D, I project breakeven soon and a price target of $124 by 2029, a 91% upside.
Read More
Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.
Read More
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better?
Published: July 28, 2025 by: 24/7 Wall Street
Sentiment: Positive
Tempus AI and Recursion Pharmaceuticals are fine ways to play the AI revolution from the health angle.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Tempus AI, Inc. of Class Action Lawsuit and Upcoming Deadlines - TEM
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
TEM Securities Lawsuit Filed Against Tempus AI, Inc. Contact the DJS Law Group to Discuss Your Rights
Published: July 28, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , July 28, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of securities laws. Shareholders who purchased the Company's securities between August 6, 2024, and May 27, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 12, 2025.
Read More
About Tempus AI, Inc. (TEM)
- IPO Date 2024-06-14
- Website https://www.tempus.com
- Industry Medical - Healthcare Information Services
- CEO Eric P. Lefkofsky
- Employees 2400